Your company account is blocked and you cannot place orders. If you have questions, please contact your company administrator.

surinabant - ≥98%, high purity , Cannabinoid CB1 receptor antagonist, CAS No.288104-79-0, Cannabinoid CB1 receptor antagonist

Item Number
S614268
Grouped product items
SKUSizeAvailabilityPrice Qty
S614268-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$589.90
S614268-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$825.90
S614268-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,444.90

Basic Description

Synonyms5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide | DTXSID2047357 | UNII-SF8R9VCB0X | SR147778 | SR-147778 | Surinabant | Surinabant [INN] | SF8R9VCB0X | SR 147778 | CHEMBL189676
Specifications & PurityMoligand™, ≥98%
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeANTAGONIST
Mechanism of actionCannabinoid CB1 receptor antagonist
Product Description

Surinabant, a cannabinoid CB1 antagonist, is used potentially for the treatment of obesity and alcoholism.

Product Properties

ALogP7

Associated Targets(Human)

CNR1 Tclin Cannabinoid receptor 1 (2 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CNR2 Tchem Cannabinoid receptor 2 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CNR1 Tclin Cannabinoid CB1 receptor (20913 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences
Cannabinoid CB1 receptor agonistAGONISTALA218Cannabinoid CB1 receptorSINGLE PROTEINHomo sapiens

DailyMed: [1]


Cannabinoid CB1 receptor agonistAGONISTALA218Cannabinoid CB1 receptorSINGLE PROTEINHomo sapiens

DailyMed: [1]


PubMed: [1]


Cannabinoid CB1 receptor agonistAGONISTALA218Cannabinoid CB1 receptorSINGLE PROTEINHomo sapiens

PubMed: [1] , [2]


Cannabinoid CB1 receptor antagonistANTAGONISTALA218Cannabinoid CB1 receptorSINGLE PROTEINHomo sapiens

PubMed: [1]


Cannabinoid CB1 receptor antagonistANTAGONISTALA218Cannabinoid CB1 receptorSINGLE PROTEINHomo sapiens

Other: [1]


Cannabinoid CB1 receptor antagonistANTAGONISTALA218Cannabinoid CB1 receptorSINGLE PROTEINHomo sapiens

PubMed: [1] , [2]


Wikipedia: [1]


Cannabinoid CB1 receptor antagonistANTAGONISTALA218Cannabinoid CB1 receptorSINGLE PROTEINHomo sapiens

PubMed: [1]


Cannabinoid CB1 receptor agonistAGONISTALA218Cannabinoid CB1 receptorSINGLE PROTEINHomo sapiens

PubMed: [1]


Wikipedia: [1]


Cannabinoid CB1 receptor antagonistANTAGONISTALA218Cannabinoid CB1 receptorSINGLE PROTEINHomo sapiens

PubMed: [1]


Cannabinoid CB1 receptor inverse agonistINVERSE AGONISTALA218Cannabinoid CB1 receptorSINGLE PROTEINHomo sapiens

PubMed: [1]


Names and Identifiers

IUPAC Name 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-piperidin-1-ylpyrazole-3-carboxamide
INCHI InChI=1S/C23H23BrCl2N4O/c1-2-18-21(23(31)28-29-12-4-3-5-13-29)27-30(20-11-10-17(25)14-19(20)26)22(18)15-6-8-16(24)9-7-15/h6-11,14H,2-5,12-13H2,1H3,(H,28,31)
InChi Key HMXDWDSNPRNUKI-UHFFFAOYSA-N
Canonical SMILES CCc1c(nn(c1c1ccc(cc1)Br)c1ccc(cc1Cl)Cl)C(=O)NN1CCCCC1
Isomeric SMILES CCC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Br
PubChem CID 9849616
Molecular Weight 522.26

Certificates

C of A & Other Certificates

Find and download the COA for your product by matching the lot number on the packaging.

6 results found

Lot NumberCertificate TypeDateItem
J2421753Certificate of AnalysisJul 19, 2024 S614268
J2421754Certificate of AnalysisJul 19, 2024 S614268
J2421755Certificate of AnalysisJul 19, 2024 S614268
J2421756Certificate of AnalysisJul 19, 2024 S614268
J2421757Certificate of AnalysisJul 19, 2024 S614268
J2421758Certificate of AnalysisJul 19, 2024 S614268

Related Documents

References

1. Janero DR, Makriyannis A.  (2009)  Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis..  Expert Opin Emerg Drugs,  14  (1): (43-65).  [PMID:19249987] [10.1021/op500134e]
2. Lallemand F, De Witte P.  (2006)  SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats..  Alcohol,  39  (3): (125-34).  [PMID:17127132] [10.1021/op500134e]
3. Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, Pério A, Poncelet M, Maruani J, Arnone M, Finance O et al..  (2004)  SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization..  J Pharmacol Exp Ther,  310  (3): (905-14).  [PMID:15131245] [10.1021/op500134e]

Solution Calculators